EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers

Marvin A. Soriano-Ursúa, Marlet Martínez-Archundia, Ahmet Kilic, Teresa Pérez-Capistran, Miriam A. Hernández-Zamora, Juan E. López-Ramos, Eunice D. Farfán-García

Scientia Pharmaceutica · 19.03.2025 · 93 (1) · 14

DOI: 10.3390/scipharm93010014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientia Pharmaceutica, online erschienen am 19.03.2025. Verfasst von Marvin A. Soriano-Ursúa und 6 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaria de Investigación y Posgrado del Instituto Politécnico Nacional.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Boron-containing compounds (BCCs) have been proposed for the treatment of diabetes and its complications. Recent studies have reported an improvement in the design and development of pharmaceutical formulations (often gels) containing boric acid applied to the foot ulcers of humans diagnosed with diabetes. The proposed mechanisms of action of boric acid include antimicrobial effects, the modulation of inflammation and metabolism, and the induction of cell differentiation. On the other hand, recent studies have suggested that boronic acids are potent antibacterial and antifungal compounds, effective modulators of inflammation, and inducers of vascular regeneration as well as inducers of healing, and they confer attractive properties such as adhesion, interaction, and the formation of complexes in formulations. Moreover, only a handful of studies conducted in animals have suggested the effective role of some BCCs as potent enhancers of wound healing, including their actions on induced and/or infected wounds in animals with disrupted metabolism. Also, it should be mentioned that no strong interactions between boric acid and the boronic acids present in formulations have been described. The developed combination could act as an additive and complementary therapy in the treatment of diabetic ulcers in humans. Further studies are required to support the hypothesis that this combination acts through diverse mechanisms to improve healing while avoiding or limiting a local or disseminated infection. Furthermore, the safety of BCCs used for foot ulcers should be established, as should the role of these formulations as a complementary therapy in current protocols for treating patients with diabetic foot ulcers.

Förderung

  • Secretaria de Investigación y Posgrado del Instituto Politécnico Nacional

Zitieren

APA

Soriano-Ursúa, M. A., Martínez-Archundia, M., Kilic, A., Pérez-Capistran, T., Hernández-Zamora, M. A., López-Ramos, J. E., & Farfán-García, E. D. (2025). Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers. Scientia Pharmaceutica, 93(1), 14. https://doi.org/10.3390/scipharm93010014

Vancouver

Soriano-Ursúa MA, Martínez-Archundia M, Kilic A, Pérez-Capistran T, Hernández-Zamora MA, López-Ramos JE, et al. Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers. Scientia Pharmaceutica. 2025;93(1):14. doi:10.3390/scipharm93010014

BibTeX
@article{SorianoUrsa2025,
  author = {Soriano-Ursúa, Marvin A. and Martínez-Archundia, Marlet and Kilic, Ahmet and Pérez-Capistran, Teresa and Hernández-Zamora, Miriam A. and López-Ramos, Juan E. and Farfán-García, Eunice D.},
  title = {Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers},
  journal = {Scientia Pharmaceutica},
  year = {2025},
  volume = {93},
  number = {1},
  pages = {14},
  doi = {10.3390/scipharm93010014}
}
Kostenlos starten →